142 related articles for article (PubMed ID: 6420445)
21. Evidence for increased dopaminergic and opioid activity in patients with hypothalamic hypogonadotropic amenorrhea.
Quigley ME; Sheehan KL; Casper RF; Yen SS
J Clin Endocrinol Metab; 1980 May; 50(5):949-54. PubMed ID: 6246138
[TBL] [Abstract][Full Text] [Related]
22. Thermoregulatory and endocrine effects of a low dose of danazol in postmenopausal women: interaction with the effect of naloxone.
Cagnacci A; Melis GB; Paoletti AM; Soldani R; Fioretti P
Life Sci; 1991; 48(11):1051-8. PubMed ID: 1900094
[TBL] [Abstract][Full Text] [Related]
23. Naloxone stimulation of luteinizing hormone secretion in the female monkey: influence of endocrine and experimental conditions.
Van Vugt DA; Bakst G; Dyrenfurth I; Ferin M
Endocrinology; 1983 Nov; 113(5):1858-64. PubMed ID: 6414806
[TBL] [Abstract][Full Text] [Related]
24. Objective techniques for the assessment of postmenopausal hot flashes.
Tataryn IV; Lomax P; Meldrum DR; Bajorek JG; Chesarek W; Judd HL
Obstet Gynecol; 1981 Mar; 57(3):340-4. PubMed ID: 7465149
[TBL] [Abstract][Full Text] [Related]
25. Endogenous opiates modulate pulsatile luteinizing hormone release in humans.
Ropert JF; Quigley ME; Yen SS
J Clin Endocrinol Metab; 1981 Mar; 52(3):583-5. PubMed ID: 6780598
[TBL] [Abstract][Full Text] [Related]
26. Effects of naloxone and an enkephalin analog on serum prolactin, cortisol, and gonadotropins in the chimpanzee.
Gosselin RE; Blankstein J; Dent DW; Hobson WC; Fuller GB; Reyes FI; Winter JS; Faiman C
Endocrinology; 1983 Jun; 112(6):2168-73. PubMed ID: 6406210
[TBL] [Abstract][Full Text] [Related]
27. Naloxone does not interfere with the dopamine-induced decrease in gonadotropin secretion in women with polycystic ovarian disease.
Paradisi R; Margrini O; Venturoli S; Fabbri R; Porcu E; Stanzani L; Flamigni C
Horm Metab Res; 1985 Jan; 17(1):29-31. PubMed ID: 3917966
[TBL] [Abstract][Full Text] [Related]
28. Core body temperature and circadian rhythm of hot flashes in menopausal women.
Freedman RR; Norton D; Woodward S; Cornélissen G
J Clin Endocrinol Metab; 1995 Aug; 80(8):2354-8. PubMed ID: 7629229
[TBL] [Abstract][Full Text] [Related]
29. Treatment of hot flashes with transdermal estradiol administration.
Steingold KA; Laufer L; Chetkowski RJ; DeFazio JD; Matt DW; Meldrum DR; Judd HL
J Clin Endocrinol Metab; 1985 Oct; 61(4):627-32. PubMed ID: 3928674
[TBL] [Abstract][Full Text] [Related]
30. The effect of naloxone on endogenous opioid regulation of pituitary gonadotropins and prolactin during the menstrual cycle.
Snowden EU; Khan-Dawood FS; Dawood MY
J Clin Endocrinol Metab; 1984 Aug; 59(2):298-302. PubMed ID: 6330154
[TBL] [Abstract][Full Text] [Related]
31. Secretory patterns and rates of gonadotropin-releasing hormone, follicle-stimulating hormone, and luteinizing hormone revealed by intensive sampling of pituitary venous blood in the luteal phase mare.
Irvine CH; Alexander SL
Endocrinology; 1993 Jan; 132(1):212-8. PubMed ID: 8419124
[TBL] [Abstract][Full Text] [Related]
32. Evidence that estrogens inhibit LH secretion through opioids in postmenopausal women using naloxone.
Melis GB; Paoletti AM; Gambacciani M; Mais V; Fioretti P
Neuroendocrinology; 1984 Jul; 39(1):60-3. PubMed ID: 6087184
[TBL] [Abstract][Full Text] [Related]
33. Further delineation of hypothalamic dysfunction responsible for menopausal hot flashes.
Gambone J; Meldrum DR; Laufer L; Chang RJ; Lu JK; Judd HL
J Clin Endocrinol Metab; 1984 Dec; 59(6):1097-102. PubMed ID: 6436285
[TBL] [Abstract][Full Text] [Related]
34. Effect of naloxone on luteinizing hormone, follicle-stimulating hormone, and prolactin secretion in the different phases of the estrous cycle.
Piva F; Maggi R; Limonta P; Motta M; Martini L
Endocrinology; 1985 Aug; 117(2):766-72. PubMed ID: 3926461
[TBL] [Abstract][Full Text] [Related]
35. Reduced frequency of pulsatile luteinizing hormone secretion in the luteal phase of the rhesus monkey. Involvement of endogenous opiates.
Van Vugt DA; Lam NY; Ferin M
Endocrinology; 1984 Sep; 115(3):1095-101. PubMed ID: 6745188
[TBL] [Abstract][Full Text] [Related]
36. Sex steroids modulate prolactin response to naloxone in postmenopausal women.
Melis GB; Gambacciani M; Paoletti AM; Mais V; Cagnacci A; Petacchi FD; Fioretti P
Neuroendocrinology; 1985 Aug; 41(2):138-41. PubMed ID: 2995857
[TBL] [Abstract][Full Text] [Related]
37. The influence of severe illness on gonadotropin secretion in the postmenopausal female.
Warren MP; Siris ES; Petrovich C
J Clin Endocrinol Metab; 1977 Jul; 45(1):99-104. PubMed ID: 874069
[TBL] [Abstract][Full Text] [Related]
38. Short-term effects of ovariectomy: the opioid control of LH secretion in fertile climacteric and postmenopausal women.
Petraglia F; Comitini G; D'Ambrogio G; Volpe A; Facchinetti F; Alessandrini G; Genazzani AR
J Endocrinol Invest; 1985 Aug; 8(4):325-30. PubMed ID: 2999209
[TBL] [Abstract][Full Text] [Related]
39. Opioid control of LH secretion in humans: menstrual cycle, menopause and aging reduce effect of naloxone but not of morphine.
Petraglia F; Porro C; Facchinetti F; Cicoli C; Bertellini E; Volpe A; Barbieri GC; Genazzani AR
Life Sci; 1986 Jun; 38(23):2103-10. PubMed ID: 3086650
[TBL] [Abstract][Full Text] [Related]
40. Differing responses of plasma bioactive and immunoreactive follicle-stimulating hormone and luteinizing hormone to gonadotropin-releasing hormone antagonist and agonist treatments in postmenopausal women.
Matikainen T; Ding YQ; Vergara M; Huhtaniemi I; Couzinet B; Schaison G
J Clin Endocrinol Metab; 1992 Sep; 75(3):820-5. PubMed ID: 1517372
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
